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SUMMARY
The cJun NH2-terminal kinase (JNK)-signaling
pathway is implicated in metabolic syndrome,
including dysregulated blood glucose concentration
and insulin resistance. Fibroblast growth factor 21
(FGF21) is a target of the hepatic JNK-signaling
pathway and may contribute to the regulation of gly-
cemia. To test the role of FGF21, we establishedmice
with selective ablation of the Fgf21 gene in hepato-
cytes. FGF21 deficiency in the liver caused marked
loss of FGF21 protein circulating in the blood. More-
over, the protective effects of hepatic JNK deficiency
to suppress metabolic syndrome in high-fat diet-fed
mice were not observed in mice with hepatocyte-
specific FGF21 deficiency, including reduced blood
glucose concentration and reduced intolerance to
glucose and insulin. Furthermore, we show that
JNK contributes to the regulation of hepatic FGF21
expression during fasting/feeding cycles. These
data demonstrate that the hepatokine FGF21 is a
key mediator of JNK-regulated metabolic syndrome.
INTRODUCTION
The cJun NH2-terminal kinase (JNK)-signaling pathway is acti-
vated by metabolic stress and contributes to the development
of metabolic syndrome in response to the consumption of a
high-fat diet (HFD), including obesity, hyperglycemia, and insu-
lin resistance (Sabio and Davis, 2010). JNK plays different roles
in multiple tissues to cause these phenotypes. Thus, JNK in the
hypothalamus and pituitary gland suppress energy expenditure
to cause obesity (Belgardt et al., 2010; Sabio et al., 2010a; Ver-
nia et al., 2013), and JNK in macrophages promotes chronic
inflammation to cause insulin resistance (Han et al., 2013).
JNK in peripheral tissues also contributes to the development
of insulin resistance, including adipose tissue, liver, and muscle
(Sabio et al., 2008, 2010b; Sabio and Davis, 2010). Interestingly,
hepatic JNK deficiency causes systemic protection against in-
sulin resistance in HFD-fed mice (Vernia et al., 2014). The mech-
anism of systemic protection may be caused by JNK-mediated
repression of the peroxisome proliferator-activated receptor a
(PPARa)/fibroblast growth factor 21 (FGF21)-signaling axis (Ver-
nia et al., 2014).
FGF21 circulates in the blood and is a potent regulator of
metabolism (Owen et al., 2015). The effects of FGF21 are medi-
ated by binding to FGF receptors (FGFR1c, 2c, or 3c) together
with the obligate co-receptor bKlotho (Owen et al., 2015). Clin-
ical trials using FGF21 analogs demonstrate improved dyslipi-
demia in humans (Gaich et al., 2013; Dong et al., 2015). Murine
studies demonstrate that the liver is a target of the metabolic
actions of FGF21 by regulating fatty acid oxidation, ketogen-
esis, gluconeogenesis, and lipogenesis (Potthoff et al., 2012).
Indeed, FGF21 deficiency is associated with increased hepatic
steatosis, fibrosis, and inflammation (Fisher et al., 2014; Tanaka
et al., 2015). Direct effects of FGF21 on the liver may contribute
to these hepatic responses, but recent studies indicate that
FGF21 primarily mediates these effects by indirect mechanisms
that initally target other tissues, including the CNS and adipose
tissue (Owen et al., 2015). The major hepatic action of FGF21
mediated by adipose tissue is the PPARg-induced expression
of the adipokine adiponectin (Holland et al., 2013; Lin et al.,
2013). FGF21 also acts on the hypothalamus-pituitary axis to
regulate adrenal glucocorticoid secretion during starvation-
induced hepatic gluconeogenesis (Liang et al., 2014). More-
over, FGF21 acts on the hypothalamus within the suprachias-
matic nucleus (Owen et al., 2014) and the paraventricular
nucleus (Douris et al., 2015) to increase sympathetic outflow
to peripheral tissues, including the liver. This sympathetic activ-
ity also targets brown fat and beige/brite cells in sub-cutaneous
white fat depots (Douris et al., 2015), and it may contribute to
the blood glucose-lowering actions of FGF21 by causing
increased UCP1-dependent energy expenditure (Kwon et al.,
2015).
The purpose of the study reported here was to test the role of
FGF21 in the metabolic response to hepatic JNK activation. We
show that hepatic JNK deficiency in HFD-fed mice causes
reduced hyperglycemia and improved tolerance to glucose
and insulin. These effects of JNK deficiency were not detected
in mice with hepatocyte-specific ablation of the Fgf21 gene.
Collectively, these data demonstrate that FGF21 is required for
glycemic regulation by hepatic JNK.
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RESULTS AND DISCUSSION
JNK Signaling Suppresses Fgf21 Gene Expression
Studies of mice with compound ablation of the Mapk8 plus
Mapk9 genes (also known as Jnk1 and Jnk2) in the liver demon-
strate increased expression of PPARa target genes, including
Fgf21 (Vernia et al., 2014). The JNK-signaling pathway can there-
fore repress PPARa signaling. To obtain additional evidence to
support this conclusion, we examined the effect of a specific
small molecule inhibitor of JNK protein kinase activity (JNK-
in-8; Zhang et al., 2012) on PPARa-dependent gene expression,
including Acox1, Ehhadh, and Fgf21. We found that treatment of
wild-type hepatocytes, but not Ppara/ hepatocytes, with JNK-
in-8 caused increased PPARa-dependent gene expression in
response to the PPARa agonist WY14043 (Figure 1A). These
data support the conclusion that JNK signaling represses
PPARa target gene expression, including Fgf21. This PPARa
pathway is important for starvation-induced FGF21 expression
(Badman et al., 2007; Inagaki et al., 2007), while additional path-
ways (e.g., ATF4, ChREBP, GCN2, NRF2, and SIRT1) play key
roles in FGF21 expression caused by other dietary stresses,
Figure 1. Inhibition of the Hepatic JNK-
Signaling Pathway Promotes FGF21
Expression
(A) Primary hepatocytes were treated without or
with JNK inhibitor (JNK-in-8) or the PPARa agonist
WY14043 (Fibrate). The expression of the PPARa
target genes Acox1, Ehhadh, and Fgf21 mRNA
was examined by measurement of mRNA using
qPCR (mean ± SEM; n = 6). PPARa deficiency
suppressed gene expression, including in cells
treated with fibrate plus JNK-in-8 (***p < 0.001).
(B and C) Primary hepatocytes were prepared
from control mice and mice with liver-specific
deficiency of MKK4, MKK7, or JNK1/2. Genomic
DNA was examined by PCR to detect gene abla-
tions (B). Primary hepatocytes treated without
or with TNF-a were examined by immunoblot
analysis (C).
(D) The blood concentration of FGF21 in wild-type
and MLK2 plus MLK3-deficient (Map3k10/
Map3k11/) mice fed ad libitum was measured
by ELISA (mean ± SEM; n = 6; *p < 0.05).
(E) Expression of Acox1, Ehhadh, and Fgf21
mRNA by primary hepatocytes prepared from
control mice and mice with liver-specific defi-
ciency of MKK4 or MKK7 was examined by qPCR
(mean ± SEM; n = 6; *p < 0.05, **p < 0.01, and
***p < 0.001).
including low-protein and high-carbohy-
drate diets (Iizuka et al., 2009; Chartoum-
pekis et al., 2011; De Sousa-Coelho et al.,
2012; Li et al., 2014).
To obtain independent evidence for
repression of Fgf21 expression by the
JNK-signaling pathway, we examined
the effect of defects in the upstream regu-
latory mechanism that activates JNK. It is
established that JNK activation is medi-
ated by the protein kinases MKK4 and MKK7 (Tournier et al.,
2001). Disruption of theMap2k4 gene or theMap2k7 gene in he-
patocytes partially suppressed JNK signaling, indicated by
reduced phosphorylation of JNK and cJun (Figures 1B and 1C).
Incontrast, compoundablationofMap2k4plusMap2k7 (likecom-
pound ablation ofMapk8 plusMapk9) prevented JNK signaling in
hepatocytes (Figure 1C). Analysis of Fgf21 mRNA expression
demonstrated that both MKK4 deficiency and MKK7 deficiency
caused increased Fgf21 expression, but compound MKK4 plus
MKK7deficiency strongly increasedFgf21expression (Figure 1E).
Similarly, compound deficiency of the mixed-lineage protein ki-
nases MLK2 plus MLK3, which function as activators of MKK4
and MKK7 in response to metabolic stress (Kant et al., 2013),
causes increased expression of FGF21 circulating in the blood
(Figure 1D). Together, these data demonstrate that the JNK-
signaling pathway acts to suppress FGF21 expression.
To test the role of JNK signaling during physiological regula-
tion of FGF21 expression, we investigated the effect of fasting
and re-feeding mice on hepatic FGF21 expression and JNK ac-
tivity. It is established that FGF21 expression is strongly induced
by starvation and that re-feeding rapidly represses FGF21
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expression (Potthoff et al., 2012). Previous studies have demon-
strated that hepatic JNK is activated by over-nutrition whenmice
are fed a HFD (Sabio and Davis, 2010). However, it was not
known whether hepatic JNK is acutely regulated by fasting and
re-feeding. We therefore examined JNK activation in mice fed
a chowdiet (CD) ad libitum,mice fed a CDand then starved over-
night, and mice that were starved overnight and subsequently
re-fed a CD (1 hr). This analysis demonstrated the presence of
activated hepatic JNK in fed mice, a reduction in JNK activation
in starved mice, and rapid re-activation of JNK in re-fed mice
(Figure 2A). The hepatic JNK pathway is therefore acutely regu-
lated by fasting/feeding cycles. These changes in JNK pathway
activation appear to reflect the activation state of MKK7 rather
than MKK4 (Figure 2A). Interestingly, JNK activation and
FGF21 expression are anti-correlated; feeding-induced activa-
tion of JNK is associated with downregulation of FGF21 expres-
sion (Figures 2B and 2C). These data indicate that JNK-mediated
repression may contribute to the physiological regulation of
FGF21 during cycles of fasting and feeding.
Conditional Ablation of the Fgf21 Gene in Mice
We established Fgf21Loxp/LoxP mice to examine the effect of tis-
sue-specific ablation of the Fgf21 gene (Figures S1A and S1B).
To test the role of hepatic FGF21 expression, we obtained LDFgf21
mice (Alb-cre+ Fgf21LoxP/LoxP) with Fgf21 gene ablation selec-
tively in hepatocytes. Analysis of LDFgf21 mice demonstrated
no hepatic expression of Fgf21 mRNA or FGF21 protein circu-
lating in blood (Figures S1C–S1E). In contrast, FDFgf21 mice
(Adipoq-cre+ Fgf21LoxP/LoxP mice) with Fgf21 gene ablation
selectively in adipose tissue demonstrated the presence of
FGF21 protein in blood, despite the complete loss of Fgf21
mRNA expression in adipose tissue (Figures S1C–S1E). These
observations confirm that the liver is the major source of
FGF21 circulating in blood (Markan et al., 2014).
Hepatic FGF21 Deficiency Promotes Metabolic
Syndrome
We examined the effect of feeding a HFD to control mice and
mice with FGF21 deficiency in liver (LDFgf21) or adipose tissue
(FDFgf21). Measurement of body mass demonstrated increased
weight gain by LDFgf21 mice, but not FDFgf21 mice, compared
with control mice (Figures 3A and S2A). Analysis of total
body composition by 1H-MRS demonstrated that the
increased body mass was caused by accumulated fat mass
rather than increased lean mass (Figure 3B). Examination of
organ mass at necropsy indicated that the majority of the
increased weight gain was associated with increased mass
of the liver, white adipose tissue, and brown adipose tissue
(Figure S2B). Sections prepared from the liver demonstrated
that LDFgf21 mice exhibited increased hepatic steatosis
compared with FDFgf21 mice and control mice (Figure 3D).
Similarly, analysis of sections prepared from brown and white
adipose tissues demonstrated increased adipocyte hypertro-
phy in LDFgf21 mice compared with FDFgf21 mice and control
mice (Figures 3E and 3F). The increased obesity of LDFgf21
mice was associated with increased HFD-induced hyperinsuli-
nemia and circulating concentrations of the adipokines leptin
and resistin (Figures S2C–S2E). This effect of hepatic FGF21
deficiency to promote obesity is similar to observations re-
ported for whole-body FGF21 knockout mice (Badman et al.,
2009; Hotta et al., 2009).
The phenotype of LDFgf21 mice suggests that hepatic FGF21
deficiency may promote metabolic syndrome. We therefore
examined glycemic regulation in LDFgf21 mice, FDFgf21 mice,
and control mice. No significant differences in blood glucose
concentration were detected in CD-fed mice. Similarly, studies
of glucose, insulin, and pyruvate tolerance of CD-fed mice
demonstrated no differences among control mice, LDFgf21
mice, and FDFgf21 mice (Figures S3A–S3C). In contrast, the blood
glucose concentration was increased in HFD-fed LDFgf21 mice
compared with HFD-fed FDFgf21 mice and HFD-fed control
mice (Figure 3C). Furthermore, HFD-fed LDFgf21 mice were signif-
icantly more glucose intolerant (Figure 3G), more insulin resistant
(Figure 3H), and more pyruvate intolerant (Figure 3I) than
HFD-fed control mice or FDFgf21 mice.
Collectively, these data demonstrate that hepatocyte-specific
FGF21 deficiency dramatically suppresses the amount of FGF21
that circulates in the blood. Moreover, hepatocyte-specific
Figure 2. Hepatic JNK Regulates FGF21 Levels in Response to
Fasting
(A) Mice were fed a CD ad libitum, fasted overnight, or fasted overnight and
then re-fed a CD (1 hr). Liver extracts were prepared and examined by
immunoblot analysis (left). The amounts of phospho-JNK and phospho-cJun
(right) were quantitated (mean ± SEM; n = 3; *p < 0.05 and **p < 0.01).
(B and C) The amount of hepatic Fgf21 mRNA (B) was measured by qPCR
(mean ± SEM; n = 6–10). The blood concentration of FGF21 (C) was measured
by ELISA (mean ± SEM; n = 10–12). Statistically significant differences be-
tween LWT and LDJ1,J2 mice are indicated (**p < 0.01).
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FGF21 deficiency promotes obesity and hallmarks of metabolic
syndrome in HFD-fed mice, including increased hyperglycemia
and hyperinsulinemia together with intolerance to glucose, pyru-
vate, and insulin.
Fgf21 Gene Ablation Suppresses the Metabolic Effects
of Hepatic JNK Deficiency
Hepatic JNK deficiency causes increased expression of PPARa
target genes in the liver, including Fgf21 (Vernia et al., 2014). To
test the role of FGF21, we examined the effect of compound defi-
ciency of JNK plus FGF21 in hepatocytes by comparing LDJ1,J2
mice (Alb-cre+ Mapk8LoxP/LoxP Mapk9LoxP/LoxP) with LDJ1,J2,Fgf21
mice (Alb-cre+ Mapk8LoxP/LoxP Mapk9LoxP/LoxP Fgf21LoxP/LoxP).
No significant differences in total body mass, fat mass, or lean
mass among LDJ1,J2 mice, LDJ1,J2,Fgf21 mice, and control mice
were detected (Figures 4A and 4B). However, the HFD-induced
Figure 3. FGF21 Deficiency in Liver In-
creases HFD-Induced Obesity
(A) The total body mass gain of CD-fed and HFD-
fed mice was examined (mean ± SEM; n = 6–10;
*p < 0.05 and **p < 0.01). FGF21 deficiency in liver
or fat was studied by comparing control mice
(Fgf21LoxP/LoxP) with liver-specific FGF21-deficient
mice (LDFgf21) and adipose tissue-specific FGF21-
deficient mice (FDFgf21).
(B) The fat and lean mass of CD-fed and HFD-fed
(12 weeks) mice were measured by 1H-MRS
analysis (mean ± SEM; n = 6–10; *p < 0.05 and
**p < 0.01).
(C) The blood glucose concentration in CD-fed
and HFD-fed (12 weeks) mice starved overnight
was examined (mean ± SEM; n = 6–10; *p < 0.05
and **p < 0.01).
(D–F) Sections of liver (D), epididymal white adi-
pose tissue (WAT, E), and interscapular brown
adipose tissue (BAT, F) from CD-fed and HFD-fed
(12 weeks) mice were stained with H&E. Scale bar,
100 mm.
(G–I) Glucose tolerance test (GTT, G), insulin
tolerance test (ITT, H), and pyruvate tolerance test
(PTT, I) using HFD-fed (12 weeks) mice were
performed (mean ± SEM; n = 6–10; *p < 0.05 and
**p < 0.01).
See also Figures S1, S2, and S3.
hyperglycemia in control mice that was
suppressed by JNK deficiency (compare
control and LDJ1,J2 mice; Figure 4C) was
not detected in FGF21-deficient mice
(compare LDFgf21 and LDJ1,J2,Fgf21 mice;
Figure 4C). These data indicate that
FGF21 is essential for the effect of he-
patic JNK deficiency to suppress HFD-
induced hyperglycemia.
To examine the requirement of FGF21
for glycemic regulation, we performed
glucose, insulin, and pyruvate tolerance
tests. Studies of CD-fed mice de-
monstrated no significant differences be-
tween groups (Figures S3D–S3F), but JNK deficiency in HFD-fed
mice caused improved performance in each of these tests (Fig-
ure 4D). This effect of JNK deficiency was not detected in
FGF21-deficient mice (compare HFD-fed LDFGF21 and HFD-fed
LDJ1,J2,FGF21 mice; Figure 4D). Moreover, hepatic JNK deficiency
did not suppress HFD-induced hyperinsulinemia or circulating
concentrations of the adipokines leptin and resistin in liver-spe-
cific FGF21-deficient mice (Figure 4E). Together, these data
confirm that FGF21 is required for improved glycemic regulation
caused by hepatic JNK deficiency.
Interestingly, the effect of hepatic JNK deficiency to increase
the expression of the PPARa target genes Acox1 and Ehhadh
in HFD-fed mice was suppressed in hepatic FGF21-deficient
mice (Figure 4F). This observation suggests that FGF21 plays a
key role in the promotion of fatty acid oxidation caused by hepa-
tic JNK deficiency, consistent with the established physiological
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Figure 4. FGF21 Is Critically Required for the Metabolic Actions of Hepatic JNK
(A) The total body mass gain of CD-fed and HFD-fed mice was examined. The effect of FGF21 deficiency in liver was examined by comparing control mice
(Mapk8LoxP/LoxP Mapk9 LoxP/LoxP) and mice with liver-specific deficiency of JNK (LDJ1,J2) or JNK plus FGF21 (LDJ1,J2,Fgf21). No statistically significant differences
were detected between groups (mean ± SEM; n = 8–10).
(B) The fat and lean mass of CD-fed and HFD-fed (12 weeks) mice were measured by 1H-MRS analysis (mean ± SEM; n = 8–10).
(C) Blood glucose concentration was measured in overnight-fasted CD-fed and HFD-fed (12 weeks) mice (mean ± SEM; n = 6–10; *p < 0.05 and ***p < 0.001).
(D) GTT, ITT, and PTT using HFD-fed (12 weeks) mice were performed (mean ± SEM; n = 6–10; *p < 0.05, **p < 0.01, and ***p < 0.001).
(E) The blood concentrations of insulin, leptin, and resistin in overnight-fasted CD-fed and HFD-fed (12 weeks) mice were measured (mean ± SEM; n = 6–10;
*p < 0.05 and **p < 0.01).
(F) The expression of Acox1, Ehhadh, and Fgf21 mRNA in the liver of CD-fed and HFD-fed (12 weeks) mice were measured by qPCR (mean ± SEM; n = 6;
*p < 0.05, **p < 0.01, and ***p < 0.001).
(G) Sections of liver from CD-fed and HFD-fed (12 weeks) control, LDJ1,J2, and LDJ1,J2,Fgf21 mice were stained with H&E. Scale bar, 100 mm.
See also Figures S3 and S4.
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role of FGF21 (Badman et al., 2007). Indeed, the reduction in
HFD-induced hepatic steatosis caused by JNK deficiency was
not detected in the liver of mice with hepatic FGF21 deficiency
(Figure 4G). These data highlight the crucial role of FGF21 in he-
patic JNK signal transduction.
One pathway that mediates the hepatic actions of FGF21 is
represented by the adipokine adiponectin (Holland et al., 2013;
Lin et al., 2013). We therefore examined the expression of adipo-
nectin in control, LDFgf21, and FDFgf21 mice; these data demon-
strated that hepatic FGF21 deficiency, but not adipocyte
FGF21 deficiency, caused reduced expression of Adipoq
mRNA in epididymal white adipose tissue (Figure S4A). More-
over, studies of control, LDJ1,J2, and LDJ1,J2,Fgf21 mice indicated
that hepatic JNK deficiency caused increased adiponectin
expression that was suppressed in mice with compound hepatic
deficiency of JNK plus FGF21 (Figure S4B). Together, these data
demonstrate that the increased circulating concentration of
FGF21 caused by hepatic JNK deficiency promotes adipose
tissue expression of adiponectin. The FGF21-promoted adipo-
nectin expression, together with FGF21-promoted sympathetic
stimulation of brown and beige/brite adipose tissue, may
contribute to the improved hepatic function of mice with hepatic
JNK deficiency.
In summary, the requirement of FGF21 for the metabolic ac-
tions of hepatic JNK provides a mechanism for metabolic regu-
lation by the JNK-signaling pathway in the liver. FGF21 plays a
major role in the response to starvation, including increased he-
patic gluconeogenesis, ketogenesis, and fatty acid oxidation
(Potthoff et al., 2012). Feeding terminates this response by acti-
vation of the hepatic JNK-signaling pathway and repression of
FGF21 expression. JNK activation, therefore, provides a regula-
tory mechanism that contributes to the termination of the starva-
tion response. Conversely, starvation-induced inhibition of the
JNK pathway contributes to de-repression of FGF21 expression
and promotes adaptive responses to starvation. These data
establish a key role played by FGF21 in the metabolic response
to hepatic JNK activation caused by cycles of fasting and re-
feeding.
The interplay between hepatic JNK and FGF21 contributes to
the development of metabolic syndrome in response to diet-
induced obesity (Vernia et al., 2014). Indeed, the protective ef-
fects of hepatic JNK deficiency on insulin resistance were not
observed in mice with hepatic FGF21 deficiency (Figure 4).
This finding is similar to a report of autophagy-deficient mice
that exhibit improved metabolic syndrome that also was depen-
dent on increased FGF21 expression (Kim et al., 2013). Similarly,
FGF21 improves hyperglycemia in mice with hepatic deficiency
of the insulin receptor (Emanuelli et al., 2014). FGF21 also can
provide protection against some forms of drug-induced hepato-
toxicity (Ye et al., 2014). Together, these data demonstrate that
FGF21 can play strong protective roles in models of metabolic
and cellular dysfunction.
EXPERIMENTAL PROCEDURES
Blood Analysis
Blood glucose was measured with an Ascensia Breeze 2 glucometer (Bayer).
FGF21 was measured using the Rat/Mouse Fibroblast Growth Factor 21
ELISA kit (EZRMFGF21-26K, Millipore). Adipokines and insulin in plasma
weremeasured bymultiplexed ELISA using a Luminex 200machine (Millipore).
Glucose and Insulin Tolerance Tests
Glucose, insulin, and pyruvate tolerance tests were performed by intraperito-
neal injection of mice with glucose (1 g/kg), insulin (0.5 U/kg), or pyruvate
(1 g/kg) using methods described previously (Sabio et al., 2008).
RNA Analysis
Tissue isolated frommice starved overnight was used to prepare total RNAwith
theRNAeasymini kit (QIAGEN). Total RNA (500ng)was converted into cDNAus-
ing the high-capacity cDNA reverse transcription kit (Life Technologies). The
diluted cDNA was used for real-time qPCR analysis using a Quantstudio PCR
machine (Life Technologies). TaqMan assays (Life Technologies) were used to
quantify Acox1 (Mm01246831_m1), Adipoq (Mm00456425-m1), and Ehhadh
(Mm00619685_m1). Fgf21 expression was quantified using the primers
FGF21F67 (50-AGATGGAGCTCTCTATGGATCG-30) and FGF21R67 (50-GGGC
TTCAGACTGGTACACAT-30) with universal probe 67 (Universal Probe Library,
Roche). The relative mRNA expression was normalized by measurement of the
amount of 18S RNA in each sample using Taqman assays (catalog number
4308329, Life Technologies).
Immunoblot Analysis
Liver extracts were prepared using Triton lysis buffer (20 mM Tris [pH 7.4],
1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM b-glycer-
ophosphate, 1 mMsodium orthovanadate, 1 mMPMSF, and 10 mg/ml leupeptin
plus aprotinin). Extracts (30–50 mg protein) were examined by immunoblot
analysis by probing with antibodies to pSer63-cJUN, pJNK, pMKK4, MKK4,
pMKK7, and MKK7 (Cell Signaling Technology); JNK1/2 (BD Pharmingen);
cJUN and GAPDH (Santa Cruz Biotechnology); and b-Tubulin (Covance).
Immunocomplexes were detected by fluorescence using anti-mouse and
anti-rabbit secondary IRDye antibodies (LI-COR Biosciences) and quantitated
using the LI-COR Imaging system.
Analysis of Tissue Sections
Histology was performed using tissue fixed in 10% formalin (24 hr), dehy-
drated, and embedded in paraffin. Sections (7 mm) were cut and stained using
H&E (American Master Tech Scientific). Sections isolated from five mice per
group were examined by a board-certified pathologist who was blinded with
respect to the identity of each group of mice.
Statistical Analysis
Differences between groups were examined for statistical significance using
the Student’s test or ANOVA with the Fisher’s test.
Institutional Review Board Approval
The Institutional Animal Care and Use Committee of the University of Massa-
chusetts Medical School approved all studies using animals.
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